Download PDF

Gizeh Perez Tenorio

Ph.D. Experimental Oncology


Multidisciplinary scientist, B.Sc in Biochemistry, Ph.D. in Experimental Oncology and Two years international postdoctoral fellowship financed by the Swedish Research Council (VR).

Working in translational medicine, from in vitro models to statistical analysis in breast cancer patient materials. Experienced in molecular biology and cellular assays. Strong computer skills. Proficient in experimental design and troubleshooting. Goal-oriented team player able to collaborate with scientists from different disciplines and nationalities. Experienced in mentoring pre-graduate, master and PhD students. Multilanguage communicator in English, Swedish, Spanish and French. Seeking a collaborative and creative environment within Academia or R&D  to apply my skills and extensive experience.


Jul 2002Jun 2009

PhD in Experimental Oncology

Linköping University

Key Achievements:

  • Studied several genetic alterations in the PI3K/AKT/mTOR signaling pathway
  • Explored the clinical value of PKB/AKT expression and activation in breast cancer.
  • Deciphered the impact of PIK3CA mutations and PTEN loss in breast cancer.
  • Found that RPS6K1 and RPS6K2 had divergent roles in breast cancer and gene amplification was associated to therapy response.


Cell biology 

Confocal microscopy, time-lapse microscopy, migration, adhesion, proliferation, Cell death (apoptosis) assays, Flow Cytometry.

Monoclonal antibodies

Generation and characterization.

Cell culture

Mammalian cell lines. 

Molecular biology

Transfection, transduction, cloning, RT-PCR, ddPCR, TaqMan arrays, siRNA, Lentivirus.


Protein purification, phosphorylation, ubiquitylation.


Design, and mouse Immunization with synthetic peptides mimicking hormone receptors


Development, sandwich ELISA.

In vitro

Immunoblotting, cell fractionation, IP, pull-down.


Mentor of pre-graduate and Master students and co supervisor of a  PhD student.


GraphPad Prism, Statistica, Image J, Photoshop CS5, Lightroom, Illustrator, Excel, EndNote.

Work History

Jan 2014Dec 2015

First Research Engineer

Linköping University (LiU)

Digital droplet (ddPCR) design, test and standarization using blood, colorectal and breast cancer materials EPH Antibody validation: anti-EPHB2 and EPHB4 using siRNA, immunoblot and IHC. Validation of EPHB and ephrin-B antibodies for IHC in paraffin embedded samples LC-MS/MS analysis and in gel digestion Co-supervisor of a PhD student, master and pre-graduate students Mentor in the medical program.

Jan 2012Dec 2013


Linköping University

Designed a TaqMan gene expression array for EPH family: EPH/EFN profile in clinical material Used and interpreted data from Cell Motility array: Explored genes involved in ephrin-B2-mediated cell motility. Explored the clinical value of EPH and ephrins in breast cancer data bases

Aug 2009Oct 2011

International postdoctoral fellow

Sandford.Burnham.Prebys Medical Discovery Institute

Studied EphB4-ephrin-B2 downstream signaling pathways in vitro. Investigated EphB4 crosstalk with other receptor tyrosine kinases in breast cancer cells. Generated ephrin-B2 stable cell lines by lentiviral infection and characterized them by immunoblotting, immunofluorescence, cell adhesion, proliferation, migration and transwell assays.

Jul 2002Jun 2009

PhD student

Linköping University

Studied several genetic alterations in the PI3K/AKT/mTOR signaling pathway Explored the clinical value of PKB/AKT expression and activation in breast cancer. Deciphered the impact of PIK3CA mutations and PTEN loss in breast cancer. Found that RPS6K1 and RPS6K2 had divergent roles in breast cancer and gene amplification was associated to therapy response.

Apr 1999Jun 2002

LiU scholarship

Linköping University

Detected HER2 expression in homogenates from breast tumors by Flow Cytometry. Determined S-phase Fraction using the software ModiFit. Prepared frozen sections in the microtome to detect protein expression by immunohistochemistry.

Apr 1998Apr 1999

Research assistant

Center of Molecular Immunology

Design and characterization of synthetic peptides mimicking the oestrogen and progesterone receptors Development of ELISA to test the specificity and affinity of monoclonal antibodies recognizing synthetic peptides Development of monoclonal antibodies against estrogen and progesterone receptors Training in different immunization techniques using mice models.

Sep 1994Apr 1999

Research Assistant

National Institute of Oncology and Radiobiology

Compared two radiolabeling methods to use 99mTc coupled to a monoclonal anti-EGFR antibody as Radiopharmaceutical agent. Development of the Ascorbate/Dithionite system for direct labeling of the Ior-CEA 1 MAb with 99mTc Development of experimental system to study the role of TGFb in cancer cells


  • Cynthia Veenstra, Gizeh Pérez-Tenorio, Anna Stelling, Elin Karlsson, Sanam Mirwani Mirwani, Bo Nordenskjöld, Tommy Fornander, Olle Stål. Met and its ligand HGF are associated with clinical outcome in breast cancer. Oncotarget. 2016 DOI: 10.18632/oncotarget.9268.
  • Husa AM, Magic Z, Larsson M, Fornander T, Pérez-Tenorio G. EPH/ephrin profileand EPHB2 expression predicts patient survival in breast cancer. Oncotarget. 2016 Feb 8. doi: 10.18632/oncotarget.7246. [Epub ahead of print] PubMed PMID: 26870995.
  • Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T, Nordenskjöld B, Stål O. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. Endocr Relat Cancer. 2015 Jun;22(3):331-43. doi: 10.1530/ERC-14-0513. PubMed PMID: 25972244.
  • Karlsson E, Veenstra C, Emin S, Dutta C, Pérez-Tenorio G, Nordenskjöld B, Fornander T, Stål O. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer. Breast Cancer Res Treat. 2015 Aug;153(1):31-40. doi: 10.1007/s10549-015-3516-y. Epub 2015 Jul 25. PubMed PMID: 26208487.
  • Gizeh Pérez-Tenorio, Elin Karlsson & Olle Stål. Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer. Breast Cancer Management. 2014 September; Vol. 3, No. 5, Pages 409-421 (
  • Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, BostnerJ, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J,Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A,Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664. PubMed PMID: 24886537; PubMed Central PMCID: PMC4076632.
  • Falivelli G, Lisabeth EM, Rubio de la Torre E, Perez-Tenorio G, Tosato G, Salvucci O, Pasquale EB. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. PLoS One. 2013 Nov 29;8(11):e81445. doi:10.1371/journal.pone.0081445. eCollection 2013. PubMed PMID: 24348920; PubMed Central PMCID: PMC3857839.
  • Fohlin H, Pérez-Tenorio G, Fornander T, Skoog L, Nordenskjöld B, Carstensen J,Stål O. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. Eur J Cancer. 2013 Apr;49(6):1196-204. doi:10.1016/j.ejca.2012.12.006. Epub 2013 Jan 8. PubMed PMID: 23305873.
  • Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, SgroiDC, Nordenskjöld B, Hallbeck AL, Stål O. The mTOR effectors 4EBP1 and S6K2 arefrequently coexpressed, and associated with a poor prognosis and endocrineresistance in breast cancer: a retrospective study including patients from therandomised Stockholm tamoxifen trials. Breast Cancer Res. 2013;15(5):R96. PubMed PMID: 24131622; PubMed Central PMCID: PMC3978839.
  • Karlsson E, Waltersson MA, Bostner J, Pérez-Tenorio G, Olsson B, Hallbeck AL, Stål O. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and4EBP1. Genes Chromosomes Cancer. 2011 Oct;50(10):775-87. doi: 10.1002/gcc.20900. Epub 2011 Jul 11. PubMed PMID: 21748818.
  • Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, NordenskjöldB, Fornander T, Skoog L, Stål O. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi:10.1007/s10549-010-1058-x. Epub 2010 Oct 16. PubMed PMID: 20953835.
  • Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL.Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009 May 15;69(10):4192-201. doi: 10.1158/0008-5472.CAN-09-0042. Epub 2009 May 12. PubMed PMID: 19435893; PubMed Central PMCID: PMC2724871.
  • Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist, LE, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007 Jun 15;13(12):3577-84. PubMed PMID: 17575221.
  • Pérez-Tenorio G, Berglund F, Esguerra Merca A, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. Int J Oncol. 2006 May;28(5):1031-42. PubMed PMID: 16596219.
  • Söderlund K, Pérez-Tenorio G, Stål O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol. 2005 Jan;26(1):25-32. PubMed PMID: 15586221.
  • Stål O, Pérez-Tenorio G, Akerberg L, Olsson B, Nordenskjöld B, Skoog L, Rutqvist LE. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003;5(2):R37-44. Epub 2003 Jan 20. PubMed PMID: 12631397; PubMed Central PMCID: PMC154147.
  • Pérez-Tenorio G, Stål O; Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002 Feb 12;86(4):540-5. PubMed PMID: 11870534; PubMed Central PMCID: PMC2375266.
  • Quesada Cepero W, Pimentel González G, Oliva González J, Pérez Tenorio G, Aguiar Cabeza E, Sánchez Monzón I, Hernández Romero O, Rebustillo Sierra M. Radiolabeling of a new agent for the study of colorectal tumors]. Rev Esp Med Nucl. 1998;17(2):82-8. Spanish. PubMed PMID: 9611277.
  • Barral AM, Perez-Tenorio G, Alvarez Y, Rodriguez HM, Gonzalez M, Faxas ME,Garcia CA. Development of an experimental system for the study of transforming growth factor ß. Adv. in Mod. Biotech. 1994:2:159


  • 2015: AACR Advances in Breast Cancer Research, (October 17-20, Bellevue, Washington)
  • 2014: Mårten Fernö Breast Cancer Workshop,  (September 11-12, Villa Aske, Sweden)
  • 2014: AACR annual meeting, (April 6-9, San Diego CA )
  • 2013: Mårten Fernö Breast Cancer Workshop,  (September 12-13, Villa Aske, Sweden)
  • 2013: AACR annual meeting,  (April 6-10, Washington DC)
  • 2012: Breast Cancer Retreat, (Oct 17-18, Villa Fridhem)
  • 2012: SOTA meeting,  (Oct 25, Linköping)
  • 2007: PI3K Signaling Pathways in Disease. Keystone Simposium (February 15-10, Santa Fe, New Mexico, USA )
  • 2005 Signal transduction in Cancer: Molecular mechanisms and therapeutic opportunities, (Dec 12-13, Umeå).
  • 2005: Hormonal Regulation of Tumorigenesis. Keystone Symposium  (February 20-25, Monterey, CA, USA)
  • 2002: American Association for Cancer Research (AACR), San Francisco, CA, USA
  • 2001: State of the Art, Conference on Cancer, Stockholm, Sweden
  • 2001: Cancerfondens planeringsgrupp mötet (Klinisk betydelse av prognostiska och behandlingsprediktiva faktorer vid bröst- och prostatacancer), Lund
  • 2000: Second International Symposium on: The molecular biology of breast cancer, Norway.
  • 1997: Regional Meeting of traditional and Natural Medicine, Havana, Cuba.
  • 1996: International Workshop of Immunological   Technics , Havana, Cuba
  • 1994: Biotecnologia Havana’94 Congress (CIGB), Havana, Cuba
  • 1994: National Workshop of Immunology, (CIM) Havana, Cuba


  • 2016: Gösta Miltons donationsfond
  • 2015: Oncological Clinics foundation Linköping
  • 2014: Swedish Medical Society Travel Grant
  • 2013: LiU Cancer Travel grant
  • 2013: Lions Research award
  • 2013 and 2012: Grants from the Oncological Clinic, Linköping University
  • 2009-2011: Postdoctoral Fellowship from the Swedish Research Council
  • 2006: Lion Research award


English, French, Spanish, Swedish

Pedagogic experience

  • 2017-2012: co-supervisor of a PhD student
  • 2014: EphB4 and MET amplification in breast cancer, Anna Katharina Stelling (Master program in experimental and Medical Biosciences, Main supervisor)
  • 2013-2014: EphB4 a potential prognostic biomarker in breast cancer, Zeljana Magic (Master degree, supervisor).
  • 2013: Eph and ephrin profiling in breast cancer, Anna-Maria Husa (International Master program in Medical Biology, main supervisor)
  • Since 2012: Group Leader in Health-Etics and Learning-1 (HEL-1)
  • Since 2012: Group Leader for Medical students program semester 1B
  • Since 2012: Technical assistant in PCR and immunoblot labs for medical students.
  • 2007-2008: The role of RPS6KB2 in breast cancer, Elin Karlsson (Biomedical Research School, supervisor).
  • 2007: Caveolin-1 Mutations in Breast Cancer Using Single-Strand Conformation Analysis”. Susanna Blixt (Master Program in Medical Biology, supervisor)
  • 2003: Effects of Tamoxifen on cell cycle progression and cell death, Anna Merca (International Master’s Program in Medical Biology, supervisor).
  • 2002-2004: Histology assistant
  • 2001-2005: Group leader for the Tumour Biology course for Master students
  • 2003-2005: Tutorial Group leader for Medical Biology program (semesters 3 and 4)
  • 2001: The effect of 1,25-Dihydroxyvitamin D3 on breast cancer cells, Kristina Schildauer (degree project 10 credits C-level, supervisor).
  • 1997: The 99mTc-Ior-EGF/R3 Mab as Radiopharmaceutical agent. Comparative study of two radiolabeling methods. School of Biological Sciences/ Havana University (Opponent).
  • 1996: Ascorbate/Dithionite system: A method for direct labelling of the Ior-CEA 1 MAb with 99mTc. In vitro studies, Master Degree, Havana University


Reviewer for Carcinogenesis and Oncotarget and expert reviewer for the Master program at Linköping University

Scientific societies

  • American association for Cancer Research (AACR)
  • Swedish Medical association (SLS)


  • 2015 Linux/Unix course
  • 2014 PhD Supervison, advanced course 
  • 2003 Principles and methods in gene regulation
  • 2003 Epidemiology
  • 2003 Basics in Biostatistics
  • 2002 The role of the Problem Based Learning (PBL) supervisor
  • 2002 Introduction to the problem based learning (PBL) method
  • 2001 Ethic, research methodology and theory of science
  • 2001 Bioinformatic
  • 2000 Cellular mechanisms of carcinogenesis
  • 2000 Immunohistochemistry and in situ hybridization


 Photography amateur level